It's the second major victory this year for Definium Therapeutics and its proprietary version of LSD.

Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.

Definium Therapeutics oral LSD candidate DT120 has passed a late-stage study in generalized anxiety disorder (GAD), not even two months after reporting trial success for in…